CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
ACE-011 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00747123
NCT00747123Phase 2Completed
CompareCT.gov

A Phase 2a, Multi-Center, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ACE-011 (hActRIIA-IgG1) in Patients With Osteolytic Lesions of Multiple Myeloma

Celgene·interventional·Posted Sep 4, 2008·Updated Oct 3, 2024

In Brief

A Phase 2 clinical trial evaluating ACE-011 and Placebo for Multiple Myeloma. Completed, enrolled 30 participants across 2 sites.

Detailed Summary

Multi-center, randomized, multiple-dose study to evaluate the safety, tolerability and efficacy of ACE-011 in patients with osteolytic lesions of multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesRussia
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 4, 2008
Enrollment StartSep 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.8 years ago

Interventions

ACE-011biological

ACE-011 given by the subcutaneous route of administration monthly for 4 doses.

Placebobiological

Placebo given by the subcutaneous route of administration monthly for 4 doses.